Merck Q2 Earnings Surpass Expectations, Shares Rise

Merck's second-quarter earnings have surpassed expectations, leading to a rise in its shares. The company reported a loss per share of $0.13 for the quarter, significantly better than the estimated loss of $0.27. Revenue reached $16.6 billion, up 4% excluding currency effects and exceeding the consensus estimate of $16.41 billion.

The strong performance was driven by sales of Keytruda and Keytruda Qlex, which totaled $8.4 billion, a 4% increase excluding currency effects. Additionally, Winrevair sales rose 75% to $588 million. Robert Davis, Merck's chairman and CEO, attributed the success to 'strong execution and growing contributions from new product launches.'

Looking ahead, Merck has adjusted its full-year revenue outlook, narrowing it to a range of $66.3 billion to $67.3 billion, above the consensus estimate of $66.89 billion. However, the company has cut its adjusted earnings per share (EPS) guidance to $2.66 to $2.76, down from the previous estimate of $5.04 to $5.16.

The adjusted EPS guidance includes charges related to the acquisition of Terns, totaling $2.43 per share. Merck's full-year gross margin is now expected to be approximately 81%, down from a prior estimate of around 82%. Operating expenses are projected to reach $42.0 billion to $42.7 billion, up sharply from the previous forecast of $36.0 billion to $36.8 billion.